Literature DB >> 20142226

In vivo intravascular ultrasound analysis of the absorption rate of the Angio-Seal vascular closure device in the porcine femoral artery.

Armando Tellez1, Yanping Cheng, Geng-Hua Yi, Gerard B Conditt, Jennifer C McGregor, Alyssa M Flynn, Diane Ordanes, Gary S Mintz, Greg L Kaluza, Juan F Granada.   

Abstract

AIMS: Device-based arterial closure is currently used to achieve haemostasis following percutaneous intervention. Little is known about the in vivo patterns of device absorption. We aimed to characterise the absorption dynamics following implantation of the Angio-Seal VIP closure device (AVCD) (St. Jude Medical, St. Paul, MN, USA) by using serial intravascular ultrasound (IVUS) and histology. METHODS AND
RESULTS: Eleven AVCD were implanted following 6 Fr femoral arterial sheath in six pigs. Using carotid access, angiograms and IVUS were performed at baseline, 3, 5, 7, 14, 30 and 42 days following deployment. At termination, arteries were processed for histology at 14 (n=3), 30(n=4) and 42 days (n=4). By IVUS, following implantation the intravascular component (IC) area remained unchanged up to 14 days and decreased by 50% at 30 days and 95% by 42 days. By histology, there was a progressive decline in the IC area at 14 days and decrease by 30% at 30 days and 77% by 42 days. Histology demonstrated almost complete absorption of the IC and no signs of severe chronic granulomatous inflammation.
CONCLUSIONS: IVUS serial imaging demonstrated almost complete absorption of the IC by 42 days in normal porcine femoral arteries. There was no evidence of severe chronic granulomatous vascular inflammation demonstrated by histology.

Entities:  

Mesh:

Year:  2010        PMID: 20142226     DOI: 10.4244/eijv5i6a120

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  1 in total

1.  Long Term Outcome after Application of the Angio-Seal Vascular Closure Device in Minipigs.

Authors:  Lisa Kabelitz; Andrea Nonn; Kay W Nolte; Omid Nikoubashman; Ahmed Othman; Sarah Heringer; Martin Kramer; Martin Wiesmann; Marc A Brockmann
Journal:  PLoS One       Date:  2016-09-28       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.